BioCryst Historical Income Statement
| BCRX Stock | USD 7.45 0.39 5.52% |
Historical analysis of BioCryst Pharmaceuticals income statement accounts such as Interest Expense of 130.7 M, Selling General Administrative of 240.5 M or Total Revenue of 400.2 M can show how well BioCryst Pharmaceuticals performed in making a profits. Evaluating BioCryst Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioCryst Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioCryst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioCryst Pharmaceuticals is a good buy for the upcoming year.
BioCryst |
About BioCryst Income Statement Analysis
BioCryst Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioCryst Pharmaceuticals shareholders. The income statement also shows BioCryst investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioCryst Pharmaceuticals Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts BioCryst Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Cost Of Revenue
Cost of Revenue is found on BioCryst Pharmaceuticals income statement and represents the costs associated with goods and services BioCryst Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from BioCryst Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Interest Income is fairly stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Total Operating Expenses | 412.7M | 430.5M | 495.0M | 519.8M | Cost Of Revenue | 6.6M | 4.7M | 4.2M | 4.0M |
BioCryst Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 748K | 777K | 1.4M | 1.7M | 1.9M | 1.0M | |
| Interest Expense | 14.5M | 59.3M | 99.1M | 108.2M | 124.5M | 130.7M | |
| Selling General Administrative | 61.4M | 113.1M | 144.5M | 199.1M | 229.0M | 240.5M | |
| Total Revenue | 17.8M | 157.2M | 270.8M | 331.4M | 381.1M | 400.2M | |
| Gross Profit | 16.1M | 149.9M | 264.2M | 326.8M | 375.8M | 394.6M | |
| Other Operating Expenses | 192.6M | 334.9M | 419.3M | 435.1M | 500.4M | 525.4M | |
| Operating Income | (174.8M) | (177.7M) | (148.4M) | (103.7M) | (93.3M) | (88.7M) | |
| Ebit | (168.3M) | (122.5M) | (145.3M) | (118.0M) | (106.2M) | (100.9M) | |
| Ebitda | (167.6M) | (121.7M) | (143.9M) | (116.3M) | (104.7M) | (99.5M) | |
| Cost Of Revenue | 1.7M | 7.3M | 6.6M | 4.7M | 4.2M | 4.0M | |
| Total Operating Expenses | 190.9M | 327.6M | 412.7M | 430.5M | 495.0M | 519.8M | |
| Net Income | (196.6M) | (184.1M) | (247.1M) | (226.5M) | (203.9M) | (193.7M) | |
| Income Tax Expense | 13.8M | 2.3M | 2.7M | 310K | 356.5K | 374.3K | |
| Total Other Income Expense Net | (8.1M) | (4.1M) | (95.9M) | (122.5M) | (140.9M) | (147.9M) | |
| Income Before Tax | (182.8M) | (181.8M) | (244.4M) | (226.2M) | (260.2M) | (273.2M) | |
| Research Development | 123.0M | 208.8M | 253.3M | 216.6M | 249.1M | 261.5M | |
| Net Income From Continuing Ops | (192.2M) | (184.1M) | (247.1M) | (236.3M) | (212.7M) | (202.1M) | |
| Non Operating Income Net Other | 2.1M | 2.5M | (3.0M) | 55.1M | 63.4M | 66.6M | |
| Net Income Applicable To Common Shares | (108.9M) | (182.8M) | (184.1M) | (247.1M) | (222.4M) | (211.3M) | |
| Interest Income | 9.4M | 62K | 5.1M | 14.0M | 16.1M | 16.9M | |
| Net Interest Income | (5.1M) | (59.2M) | (94.0M) | (96.1M) | (86.5M) | (82.2M) | |
| Reconciled Depreciation | 748K | 777K | 1.4M | 1.6M | 1.9M | 1.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.